Edwards Lifesciences (NYSE: EW) reported Q3 EPS of $0.67, $0.01 better than the analyst estimate of $0.66. Revenue for the quarter came in at $1.35 billion versus the consensus estimate of $1.57 billion.

GUIDANCE:

Edwards Lifesciences sees Q4 2024 EPS of $0.53-$0.57, versus the consensus of $0.60. Edwards Lifesciences sees Q4 2024 revenue of $1.33-1.39 billion, versus the consensus of $1.396 billion.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.